Evidence map›Paper›PMID 42814329›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2027

Immunophenotyping of Cellular Therapy Products Against Oncogenic and Viral Targets.

Christopher A Lazarski, Anushree A Datar, Patrick J Hanley, Sandeep K Srivastava

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Christopher A LazarskiCenter for Cancer and Immunology Research, Children's National Hospital, Washington, DC, USA.
Anushree A DatarCenter for Cancer and Immunology Research, Children's National Hospital, Washington, DC, USA.
Patrick J HanleyCenter for Cancer and Immunology Research, Children's National Hospital, Washington, DC, USA.
Sandeep K SrivastavaCenter for Cancer and Immunology Research, Children's National Hospital, Washington, DC, USA. bio.sandeep@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Flow cytometric analysis can provide valuable information on the viability, phenotype, and therapeutic potential of cell therapy products using a minimal amount of cell numbers. In this chapter, we describe methods for the analysis of clinical products that incorporate extra considerations within the protocols to help maintain consistency and confidence of staining. This can include methods for evaluating the transduction efficiency for T cells expressing chimeric antigen receptors (CAR-T), characterizing the frequency of diverse lymphocyte populations within polyclonal cell cultures and postinfusion research samples, and measuring the activity or exhaustion in response to antigen-specific stimulation. This chapter also includes recommendations for storage and management of staining materials, frequency of compensation analysis, and reference standards.

Indexed as

Cell- and Tissue-Based TherapyFlow CytometryImmunophenotypingImmunotherapy, AdoptiveT-LymphocytesHumansReceptors, Chimeric AntigenStaining and LabelingT-Cell ExhaustionReceptors, Chimeric AntigenChimeric antigen receptors T cell (CAR-T cell)Multicolor flow cytometrySequential gatingT cell subsetsVirus-specific antigens (VST cells)

Identifiers

PMID42814329

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.